Rockwell Medical, Inc. (RMTI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Rockwell Medical, Inc. (RMTI) Healthcare & Pipeline Overview

Rockwell Medical, Inc. develops, manufactures, and distributes therapies and products for end-stage renal disease and chronic kidney disease, focusing on iron deficiency and hemodialysis. Their key products, Triferic Dialysate and Triferic AVNU, target dialysis patients in the United States and internationally, serving medium and small-sized dialysis chains and independent centers.

What Is the Investment Thesis for RMTI?

Rockwell Medical, Inc. presents a focused investment opportunity within the renal disease treatment market. The company's Triferic products offer a unique approach to managing iron deficiency in dialysis patients, potentially reducing the need for traditional IV iron supplementation and its associated risks. With a market capitalization of $30.2M, RMTI operates in a specialized niche within the broader healthcare sector. Upcoming catalysts include potential expansion of Triferic adoption among dialysis centers and progress in developing new therapeutic applications. However, the company's negative profit margin of -9.3% highlights the need for improved operational efficiency and revenue growth. The high beta of 1.71 suggests significant stock price volatility, requiring careful risk management.

Based on FMP financials and quantitative analysis

RMTI Key Highlights

Market capitalization of $30.2M indicates a small-cap company with potential for growth but also higher risk.

• Gross margin of 16.7% reflects the profitability of Rockwell Medical's products after accounting for the cost of goods sold.
• Profit margin of -9.3% signals that the company is currently operating at a loss, requiring attention to cost management and revenue generation.
• The company's focus on end-stage renal disease (ESRD) and chronic kidney disease (CKD) positions it in a specialized and growing market segment.
• Rockwell Medical's Triferic products offer a unique approach to managing iron deficiency in dialysis patients.

Who Are RMTI's Competitors?

RMTI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RMTI's Key Strengths?

Specialized product portfolio for renal disease.

• Proprietary Triferic technology.
• Established relationships with dialysis centers.

What Are RMTI's Weaknesses?

Negative profit margin.

• Limited financial resources.
• Dependence on a small number of key products.

What Could Drive RMTI Stock Higher?

Potential expansion of Triferic adoption among dialysis centers.

• Progress in developing new therapeutic applications for acute heart failure.
• Strategic partnerships to enhance product offerings and market reach.

What Are the Key Risks for RMTI?

Financial-distress signal — its Altman Z-Score of -7.69 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-15.4%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Competition from larger pharmaceutical companies with greater resources.
• Pricing pressures from healthcare providers and reimbursement policies.
• Regulatory changes impacting the approval and commercialization of new products.
• Dependence on a small number of key products for revenue generation.

What Are the Growth Opportunities for RMTI?

• Expansion of Triferic Adoption: Rockwell Medical has the opportunity to increase the adoption of Triferic Dialysate and Triferic AVNU among dialysis centers. By demonstrating the clinical and economic benefits of Triferic, the company can capture a larger share of the iron therapy market for dialysis patients. This expansion can be achieved through targeted marketing, educational programs, and partnerships with dialysis providers. The market for iron therapy in dialysis patients is estimated to be substantial, with potential for significant revenue growth.
• Development of New Therapeutic Applications: Rockwell Medical is developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure and home infusion therapy solutions. These initiatives represent growth opportunities by expanding the company's product portfolio and addressing unmet medical needs in related areas. Successful development and commercialization of these new therapies could drive revenue diversification and long-term growth.
• Geographic Expansion: Rockwell Medical can pursue geographic expansion by entering new markets outside the United States. The prevalence of chronic kidney disease is increasing globally, creating opportunities for the company to introduce its Triferic products and dialysis concentrates in international markets. This expansion would require regulatory approvals, distribution partnerships, and market-specific strategies.
• Strategic Partnerships and Acquisitions: Rockwell Medical can explore strategic partnerships and acquisitions to enhance its product offerings, expand its market reach, and strengthen its competitive position. Collaborations with other pharmaceutical companies, dialysis providers, or technology companies could accelerate innovation and drive growth. Acquisitions of complementary businesses could provide access to new markets or technologies.
• Focus on Home Hemodialysis Market: The home hemodialysis market is growing as patients seek more convenient and flexible treatment options. Rockwell Medical can capitalize on this trend by developing and offering products and services tailored to the needs of home hemodialysis patients. This includes providing dialysis concentrates, ancillary supplies, and support services for home-based treatments. The home hemodialysis market represents a significant growth opportunity for the company.

What Are RMTI's Competitive Advantages?

• Specialized product portfolio focused on renal disease.
• Proprietary Triferic technology for iron management in dialysis patients.
• Established relationships with dialysis centers and healthcare providers.

What Does RMTI Do?

Rockwell Medical, Inc., established in 1996 and headquartered in Wixom, Michigan, is a biopharmaceutical company dedicated to improving the lives of patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company develops, manufactures, and commercializes a range of therapies and products focused on treating iron deficiency and managing hemodialysis. Rockwell Medical's core offerings include Triferic Dialysate and Triferic AVNU, innovative iron therapies designed to replace iron and maintain hemoglobin levels in dialysis patients without causing iron overload. These products are crucial for managing anemia, a common and debilitating complication of kidney disease. In addition to its iron therapy solutions, Rockwell Medical manufactures and distributes a comprehensive suite of hemodialysis concentrates, including CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate. These concentrates are essential for the hemodialysis process, which removes toxins and restores vital nutrients in the bloodstream of patients with kidney failure. The company also provides ancillary products such as blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies necessary for hemodialysis procedures. Rockwell Medical primarily serves medium and small-sized dialysis chains and independent dialysis centers across the United States and internationally. Rockwell Medical is also engaged in developing other therapeutic product candidates, including treatments for hospitalized patients with acute heart failure and home infusion therapy solutions, aiming to expand its portfolio and address unmet medical needs in related areas.

What Products and Services Does RMTI Offer?

• Develops and commercializes therapies for end-stage renal disease (ESRD) and chronic kidney disease (CKD).
• Offers Triferic Dialysate and Triferic AVNU, iron therapies for dialysis patients.
• Manufactures and distributes hemodialysis concentrates, including CitraPure and RenalPure.
• Provides ancillary products such as blood tubing, fistula needles, and dialyzers.
• Develops therapeutic product candidates for acute heart failure.
• Focuses on home infusion therapy solutions.

How Does RMTI Make Money?

• Develops and manufactures pharmaceutical products and medical supplies.
• Sells products directly to dialysis centers and healthcare providers.
• Generates revenue through product sales and distribution agreements.

What Industry Does RMTI Operate In?

Rockwell Medical operates within the specialty pharmaceutical and generic drug manufacturing industry, specifically targeting the renal disease market. This market is driven by the increasing prevalence of chronic kidney disease and the growing demand for dialysis treatments. The competitive landscape includes larger pharmaceutical companies and specialized dialysis product suppliers. Rockwell Medical differentiates itself through its focus on iron management in dialysis patients with its Triferic products. The industry is subject to stringent regulatory requirements and pricing pressures, impacting profitability and market access.

Who Are RMTI's Key Customers?

• Medium and small-sized dialysis chains.
• Independent dialysis centers.
• Hospitals and healthcare facilities.

Wall Street analysts project Rockwell Medical, Inc. revenue of about $72.5M for fiscal 2026, with EPS near $-0.88.

Rockwell Medical, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 41.0% below estimates on average.

Rockwell Medical, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -7.69 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Rockwell Medical, Inc. stands at -15.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 9.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.74 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -27.8%, the inverse of the P/E and a quick read on earnings relative to price.

Rockwell Medical, Inc. (RMTI) Valuation Context

Valued at $30.2M, RMTI is classified as a micro-cap stock. Relative to its peer group, RMTI's quantitative score of 23/100 is below the peer average of 62/100.

RMTI Revenue & Earnings Trend

In Q2 2026, RMTI generated $17.8M in top-line revenue, marking a sequential increase of 2.6%. The company recorded a net loss of $1.2M, with diluted EPS of $-0.34. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, RMTI averaged $-0.35 in diluted EPS.

Company Profile

Rockwell Medical, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Wixom, US. The company is led by CEO Mark Strobeck. RMTI has traded publicly since 1998.

RMTI Financials

RMTI Latest News

No recent news available for RMTI.

RMTI Analyst Consensus

RMTI MoonshotScore

Common Questions About RMTI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources